Discontinued — last reported Q4 '23
Other Interventional Solutions — Sales to Customers
Johnson & Johnson Other Interventional Solutions — Sales to Customers remained flat by 0.0% to $89.00M in Q4 2023 compared to the prior quarter. Year-over-year, this metric grew by 7.2%, from $83.00M to $89.00M. Over 2 years (FY 2021 to FY 2023), Other Interventional Solutions — Sales to Customers shows relatively stable performance with a 1.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market adoption and successful commercialization of the company's interventional medical technologies, while a decrease may signal competitive pressure or reduced clinical demand.
Detailed definition
This metric represents the total revenue generated from the sale of specialized medical devices and interventional techn...
Peer comparison
Comparable to revenue reported for specialized medical device segments or interventional cardiology/neurology product lines at peer healthcare conglomerates.
jnj_segment_other_interventional_solutions_sales_to_customersHistorical Data
| FY'21 | FY'22 | FY'23 | |
|---|---|---|---|
| Value | $348.00M | $332.00M | $356.00M |
| YoY Change | — | -4.6% | +7.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's other interventional solutions — sales to customers?
- Johnson & Johnson (JNJ) reported other interventional solutions — sales to customers of $89.00M in Q4 2023.
- How has Johnson & Johnson's other interventional solutions — sales to customers changed year-over-year?
- Johnson & Johnson's other interventional solutions — sales to customers increased by 7.2% year-over-year, from $83.00M to $89.00M.
- What is the long-term trend for Johnson & Johnson's other interventional solutions — sales to customers?
- Over 2 years (2021 to 2023), Johnson & Johnson's other interventional solutions — sales to customers has grown at a 1.1% compound annual growth rate (CAGR), from $348.00M to $356.00M.
- What does other interventional solutions — sales to customers mean?
- The total revenue earned from the company's specialized interventional medical device product line.